RxDoctor Payments Data

Dianne Okonsky

Family · Orlando, FLNPI 1881674505

Payments from drug & device makers

$8,929in general payments, 2019–2025

Across 446 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$703
  • Bristol Myers Squibb$671
  • AstraZeneca$453
  • Regeneron Healthcare Solutions, Inc.$416
  • Astellas Pharma US Inc$381
  • Merck$374
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$8,56196%
  • Education$3684%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis44$703
Bristol Myers Squibb34$671
AstraZeneca25$453
Regeneron Healthcare Solutions, Inc.18$416
Astellas Pharma US Inc16$381
Merck17$374
Incyte Corporation13$330
Sanofi13$311
E.r. Squibb & Sons, L.L.C.14$299
Daiichi Sankyo Inc.14$275
EMD Serono, Inc.6$273
Takeda Pharmaceuticals U.S.A., Inc.8$269
Johnson & Johnson14$240
Amgen18$227
Genentech USA, Inc.12$225
Pharmaessentia USA Corporation10$216
Lilly USA, LLC11$182
Exelixis Inc.10$176
Sumitomo Pharma America, Inc.10$155
Coherus Oncology, Inc.8$151
Blueprint Medicines Corporation8$151
Recordati_rare_diseases_inc.3$137
Pfizer7$134
Stemline Therapeutics Inc.6$132
Beone Medicines USA, Inc.6$127
Deciphera Pharmaceuticals Inc.5$115
GSK7$114
Array Biopharma Inc6$111
Seagen Inc.7$107
Eisai Inc.6$107
Pharmacosmos Therapeutics Inc.4$103
Ipsen Biopharmaceuticals, Inc5$103
Tersera Therapeutics LLC4$95
Bayer5$93
AbbVie4$89
Jazz Pharmaceuticals Inc.4$84
Kyowa Kirin, Inc.3$72
Boehringer Ingelheim3$69
Sobi, Inc3$61
Beigene USA, Inc.3$44
Mirati Therapeutics, Inc.3$43
Caris MPI, Inc.2$43
AVEO Pharmaceuticals, Inc.2$41
Iovance Biotherapeutics, Inc.2$36
Progenics Pharmaceuticals, Inc.2$35
Immunogen, Inc.2$33
Janssen Scientific Affairs, LLC1$30
Karyopharm Therapeutics Inc.2$29
Tempus AI, Inc1$26
Syndax Pharmaceuticals, Inc.1$24
Myovant Sciences Inc.2$24
Agios Pharmaceuticals, Inc.1$20
Spectrum Pharmaceuticals Inc.1$20
Paratek Pharmaceuticals, Inc.1$19
Taiho Oncology, Inc.1$17
Geron Corporation1$17
Puma Biotechnology, Inc.1$15
Fennec Pharmaceuticals, Inc.1$15
ADC Therapeutics America, Inc.1$15
Verity Pharmaceuticals Inc.1$15

How this compares

$8,929 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$2,278
Medicare patients
25
Services billed
29

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate12$207,788
CalquenceAcalabrutinib Maleate13$100,418
Letrozole34$1,194
Anastrozole26$323
Levocetirizine Dihydrochloride11$247
Gabapentin13$95
Acyclovir11$60
Levothyroxine Sodium12$33

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$330$207,78812 claims
AstraZenecaCalquence$453$100,41813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →